Healthcare / BiotechnologyStockholm
$1.43
-0.02 (-1.10%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-109.3M · quality 54.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
11/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$29M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-267.9%
↓Gross Margin
N/A
•Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
1.00x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-108.9M · FCF $-109.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Net Income | $-108.9M | $-108.9M | $-96.1M | $-113.3M | $-112.8M |
| EBITDA | $-108.8M | $-108.8M | $-96.1M | $-113.3M | $-112.8M |
| EPS | -6.04 | -6.04 | -8.62 | -10.36 | -15.36 |
| Balance Sheet | |||||
| Current Ratio | 7.13 | 7.13 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-109.3M | $-109.3M | $-94.8M | $-116.0M | $-102.1M |
| Returns | |||||
| ROE | -267.9% | -267.9% | -253.0% | -169.8% | -63.6% |
| Valuation | |||||
| P/B | 0.63 | 0.63 | 5.84 | 5.49 | 1.74 |
| Growth & Yield | |||||
| EPS Growth | 29.9% | 29.9% | 16.8% | 32.6% | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-91.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-8.62 → -6.04
Residual
-91.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.